Loading
Life sciences · Journal article
Nuclear Medicine Communications · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
OBJECTIVE: To evaluate the prognostic value of the PET-derived SUVmax-lactate dehydrogenase-albumin-lymphocyte (SUV-LAL) index in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with pertuzumab. METHODS: This retrospective single-center study included patients with HER2-positive metastatic breast cancer treated with pertuzumab-containing regimens between January 2018 and October 2025. Baseline clinical, pathological, laboratory, and 18F-fluorodeoxyglucose PET/computed tomography data were retrospectively collected. The SUV-LAL index was calculated as (primary tumor maximum standardized uptake value × lactate dehydrogenase)/(albumin × absolute lymphocyte count). Overall survival (OS) and progression-free survival (PFS) were evaluated using Cox proportional hazards regression analyses. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) analysis, and time-dependent ROC analyses were performed to assess prognostic performance. RESULTS: A total of 80 patients were included, of whom 36 (45.0%) died during follow-up. The SUV-LAL index remained an independent prognostic factor for OS in multivariate analysis [hazard ratio = 1.755, 95% confidence interval (CI) = 1.053-2.927; P = 0.031], together with the number of pertuzumab cycles (hazard ratio = 0.921, 95% CI = 0.872-0.972; P = 0.003). Patients with a high SUV-LAL index had significantly shorter OS and PFS than those with a low SUV-LAL index (log-rank P < 0.001 and P = 0.002, respectively). ROC analysis yielded an area under the curve (AUC) of 0.760. Compared with its individual components, the SUV-LAL index showed the strongest association with OS in univariate Cox regression analysis and achieved the highest 1-year time-dependent AUC (0.735), while maintaining acceptable prognostic performance at 3 years (AUC = 0.705). CONCLUSION: The PET-derived SUV-LAL index independently predicts OS in HER2-positive metastatic breast cancer treated with pertuzumab.